A study published in the Asian Pacific Journal of Allergy and Immunology informed about the evidence-based guidelines that are based on expert opinion on atopic dermatitis (AD) – the chronic, relapsing skin condition. These guidelines aim to facilitate improved care of patients with AD. The classical Hanifin and Rajka criteria remain the most widely used for AD diagnosis. 

Individualized care for patients with AD has been largely advocated, mainly focusing on the avoidance of triggers and skin hydration. Symptomatic treatment with topical anti-inflammatory agents likes – glucocorticoids and calcineurin inhibitors, can be advised to subside acute flares. Long-term management entails proactive therapy. Other modalities include – topical or systemic antimicrobial agents, oral antihistamines and anti-inflammatory drugs, immunotherapy, phototherapy and psychotherapy. 

Crisaborole is a new phosphodiesterase 4 inhibitor that can be used topically in AD patients in adults and children above the age of 3 months. Patients with moderate-to-severe AD who fail to respond to other systemic drugs can be started on dupilumab – a monoclonal antibody treatment, which is safe, effective and approved for use in AD. Other emerging biologicals that target the immune response are Janus kinase inhibitors.

Source: Kulthanan K, Tuchinda P, Nitiyarom R, et al. Clinical practice guidelines for the diagnosis and management of atopic dermatitis. Asian Pac J Allergy Immunol. 2021;39(3):145-55.